Venomics AI Closes $2.7 Mn to Expand Venom-Based Drug Discovery

The company plans to use the funding to expand its venom-based drug discovery platform, strengthen its research capabilities and increase its team.

Funding and Expansion Plans

Venomics AI will use the fresh capital to expand its Venom Atlas dataset, which supports research into venom-derived molecules. The company also plans to increase its artificial intelligence (AI) capabilities and laboratory screening capacity.

The funding will support hiring across venom biology, computational science and drug discovery to accelerate research and platform development.

AI-Based Drug Discovery Platform

Founded by Indian Institute of Science professor Kartik Sunagar and Vinay Prabhu, Venomics AI combines molecular sequencing, AI and laboratory testing to study venom-derived molecules.

The startup aims to identify molecules from animal venoms that could potentially be developed into drug candidates for future medical applications.

About Venomics AI

Venomics AI is a Bengaluru-based biotechnology startup originating from the Indian Institute of Science. The company focuses on venom-based drug discovery by combining biological research, molecular sequencing and artificial intelligence to identify potential therapeutic molecules.

Read Also - Visa Establishes Six Global Capability Hubs in Singapore to Advance AI, Payments and Cybersecurity